Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Multiple Sclerosis, Relapsing-Remitting Subject who had given written informed consent Subjects with definite RRMS or SPMS with relapses Subjects with EDSS 1-6 Subjects aged between 18-60 years Subjects who were escalated to mitoxantrone due to high relapse activity or MRI activity (not due to EDSS progression exclusively) Subjects who may not have a confirmed 1 point EDSS progression (0.5 points for EDSS >5.5) within the last 9 months Subjects free of relapses over the last 6 months Subjects with last mitoxantrone treatment between 1 and 6 months prior to screening Subjects treated with mitoxantrone for minimum 9 months and maximum 36 months, total cumulative dose being 40-120 mg/m^2 Female subjects who must be neither pregnant nor breast-feeding and must lack childbearing potential, as defined by either: 1. Being post-menopausal or surgically sterile,or 2. Using a hormonal contraceptive, intra-uterine device, diaphragm with spermicide or condom with spermicide for the duration of the study. Confirmation that the subject is not pregnant must be established by a negative serum or urinary human chorionic gonadotropin (hCG) test within 7 days prior to start of study treatment. A pregnancy test is not required if the subject is post menopausal or surgically sterile  Subject who has received any cytokine or anti-cytokine therapy within the 3 months prior to study Day 1 Subject who has been escalated to mitoxantrone due to EDSS progression Subject with an ongoing MS relapse Subject with PPMS Subject with SPMS without superimposed relapses Subject who has received immunomodulatory treatment other than IFN-beta or glatiramer acetate before mitoxantrone Subject who has previously received total lymphoid irradiation Subject who has received oral or systemic corticosteroids or adrenocorticotrophic hormone ACTH within 30 days of study Day 1 Subject who has received intravenous immunoglobulins or underwent plasmapheresis within the 6 months prior to study day 1 Subject who has received immunomodulatory or immunosuppressive therapy (including but not limited to cyclophosphamide, cyclosporin, methotrexate, azathioprine, linomide, teriflunomide, natalizumab, laquinimod, Campath) within the 12 months prior to study Day 1